Lunai Bioworks Unveils AI-Driven Platform to De-Risk Drug Discovery in Complex Diseases
I'm PortAI, I can summarize articles.
Lunai Bioworks Inc. has launched an AI-driven platform, Augusta, aimed at enhancing drug discovery for complex neurological disorders. The platform utilizes advanced AI to analyze patient data, identify distinct sub-diseases, and match them with effective therapies. This approach seeks to validate drug candidates in living systems, thereby reducing failure rates and expediting development timelines for pharmaceutical partners. The presentation emphasizes a shift towards "biology-first" AI strategies in biopharma, particularly for conditions like Parkinson's disease and epilepsy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments